Literature DB >> 9139209

[Terminal care medicine--basic principles and perspectives].

B Knupp1, W Stille.   

Abstract

Mesh：

Year:  1997        PMID： 9139209     DOI： 10.1007/bf03042292

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN： 0723-5003


× No keyword cloud information.
  28 in total

1.  Dyspnoea in palliative care.

Authors:  C L Davis
Journal:  BMJ       Date:  1992-11-07

Review 2.  Appropriate chemotherapy for palliating advanced cancer.

Authors:  R D Rubens; K E Towlson; A J Ramirez; S Coltart; M L Slevin; C Terrell; A R Timothy
Journal:  BMJ       Date:  1992-01-04

Review 3.  Changing concepts in palliative care.

Authors:  I Maddocks
Journal:  Med J Aust       Date:  1990-05-21       Impact factor: 7.738

4.  Palliative care in oncology: making quality the endpoint.

Authors:  S Ahmedzai
Journal:  Ann Oncol       Date:  1990-11       Impact factor: 32.976

5.  Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study.

Authors:  M Baines; D J Oliver; R L Carter
Journal:  Lancet       Date:  1985-11-02       Impact factor: 79.321

6.  Palliative care in high-tech medicine: defining the point of no return.

Authors:  C Hürny
Journal:  Support Care Cancer       Date:  1994-01       Impact factor: 3.603

7.  Oral symptoms and candida in the terminally ill.

Authors:  I G Finlay
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

8.  The physician's responsibility toward hopelessly ill patients.

Authors:  S H Wanzer; S J Adelstein; R E Cranford; D D Federman; E D Hook; C G Moertel; P Safar; A Stone; H B Taussig; J van Eys
Journal:  N Engl J Med       Date:  1984-04-12       Impact factor: 91.245

9.  Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life.

Authors:  N Coyle; J Adelhardt; K M Foley; R K Portenoy
Journal:  J Pain Symptom Manage       Date:  1990-04       Impact factor: 3.612

Review 10.  The risks and benefits of corticosteroids in advanced cancer.

Authors:  R Twycross
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.